Skip to main content
Erschienen in: Medical Oncology 3/2011

01.09.2011 | Original Paper

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

verfasst von: Chuan-Yong Mu, Jian-An Huang, Ying Chen, Cheng Chen, Xue-Guang Zhang

Erschienen in: Medical Oncology | Ausgabe 3/2011

Einloggen, um Zugang zu erhalten

Abstract

The immunohistochemical analysis was used to evaluate the expression of PD-L1 in 109 non-small cell lung cancer (NSCLC) tissues and para-tumor tissues. Associations between expressed PD-L1 and tumor histological types, degree of differentiation, and lymph node metastasis were calculated, and overall survival was assessed. Meanwhile, immunohistochemistry and immunofluorescence double labeling technique were performed to detect the expressions of PD-L1, CD1α, and CD83 on TIDC of 20 lung cancer tissues, and the expression of PD-L1 in CD1α+DCs and CD83+DCs and their significances were also explored. We found that the expression rate of PD-L1 in NSCLC was associated with histological types and overall survival. Patients with either adenocarcinoma or survival time after surgery less than 3 years showed higher expression rate of PD-L1. Furthermore, Cox model analysis indicated that PD-L1 might be regarded as a poor prognostic factor. PD-L1 could be also detected in CD1α+ immature DC in NSCLC, indicating that as a class of key anti-tumor immunocyte in tumor microenvironment, DC expressing PD-L1 itself might play an important role in keeping its immature status and contributing to tumor cells immune escape and disease progression.
Literatur
1.
Zurück zum Zitat Yasumoto K, Hanagiri T, Takenoyama M. Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 2009;57:449–57.PubMedCrossRef Yasumoto K, Hanagiri T, Takenoyama M. Lung cancer-associated tumor antigens and the present status of immunotherapy against non-small-cell lung cancer. Gen Thorac Cardiovasc Surg. 2009;57:449–57.PubMedCrossRef
2.
Zurück zum Zitat Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–14.PubMedCrossRef Blank C, Gajewski TF, Mackensen A. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy. Cancer Immunol Immunother. 2005;54:307–14.PubMedCrossRef
3.
Zurück zum Zitat XU X, et al. Clinicopathological significance of major histocompatibility complex class I-related chain A and B expression in thyroid cancer. Clin Endocrinol. 2006;91:2704–12.CrossRef XU X, et al. Clinicopathological significance of major histocompatibility complex class I-related chain A and B expression in thyroid cancer. Clin Endocrinol. 2006;91:2704–12.CrossRef
4.
Zurück zum Zitat Kaklamanis L, et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol. 1994;145:505–9.PubMed Kaklamanis L, et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol. 1994;145:505–9.PubMed
5.
Zurück zum Zitat Blank C, Brown I, Peterson AC. PD-L1/B7–H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+T cells. Cancer Res. 2004;64:1140–5.PubMedCrossRef Blank C, Brown I, Peterson AC. PD-L1/B7–H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+T cells. Cancer Res. 2004;64:1140–5.PubMedCrossRef
6.
Zurück zum Zitat Mary E, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. Exp Med. 2006;203:883–95.CrossRef Mary E, et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. Exp Med. 2006;203:883–95.CrossRef
7.
Zurück zum Zitat Fabienne H, et al. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood. 2008;112:2149–55.CrossRef Fabienne H, et al. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway. Blood. 2008;112:2149–55.CrossRef
8.
Zurück zum Zitat Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic cell defects. Nat Rev Immunol. 2004;4:941–52.PubMedCrossRef Gabrilovich D. Mechanisms and functional significance of tumor-induced dendritic cell defects. Nat Rev Immunol. 2004;4:941–52.PubMedCrossRef
9.
Zurück zum Zitat Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7.PubMedCrossRef Mountain CF. Revisions in the international system for staging lung cancer. Chest. 1997;111:1710–7.PubMedCrossRef
10.
Zurück zum Zitat Olaussen KA, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.PubMedCrossRef Olaussen KA, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983–91.PubMedCrossRef
11.
Zurück zum Zitat Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–9.PubMedCrossRef Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5:1365–9.PubMedCrossRef
12.
13.
Zurück zum Zitat Chen C, et al. Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells. Immunol. 2007;212:159–65. Chen C, et al. Expression of programmed-death receptor ligands 1 and 2 may contribute to the poor stimulatory potential of murine immature dendritic cells. Immunol. 2007;212:159–65.
14.
Zurück zum Zitat Wong RM, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007;19:1223–34.PubMedCrossRef Wong RM, et al. Programmed death-1 blockade enhances expansion and functional capacity of human melanoma antigen-specific CTLs. Int Immunol. 2007;19:1223–34.PubMedCrossRef
15.
Zurück zum Zitat Tsushima F, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T cell anergy. Blood. 2007;110:180–5.PubMedCrossRef Tsushima F, et al. Interaction between B7-H1 and PD-1 determines initiation and reversal of T cell anergy. Blood. 2007;110:180–5.PubMedCrossRef
16.
Zurück zum Zitat Blank C, et al. Blockade of PD-L1 (B7–H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119:317–27.PubMedCrossRef Blank C, et al. Blockade of PD-L1 (B7–H1) augments human tumor-specific T cell responses in vitro. Int J Cancer. 2006;119:317–27.PubMedCrossRef
17.
Zurück zum Zitat Brown JA, et al. Blockade of programmed death 1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–66.PubMed Brown JA, et al. Blockade of programmed death 1 ligands on dendritic cells enhances T cell activation and cytokine production. J Immunol. 2003;170:1257–66.PubMed
18.
Zurück zum Zitat Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.PubMed Dong H, et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.PubMed
19.
Zurück zum Zitat Matthias S. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer. 2006;13:779–95.CrossRef Matthias S. Immunesurveillance by dendritic cells: potential implication for immunotherapy of endocrine cancers. Endocr Relat Cancer. 2006;13:779–95.CrossRef
20.
Zurück zum Zitat Mary F, Barbara J. Dendritic cells: immune regulators in health and disease. Physiol Rev. 2002;82:97–130. Mary F, Barbara J. Dendritic cells: immune regulators in health and disease. Physiol Rev. 2002;82:97–130.
21.
Zurück zum Zitat Zhou LJ, Thomas F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. PNAS. 1996;93:2588–92.PubMedCrossRef Zhou LJ, Thomas F. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. PNAS. 1996;93:2588–92.PubMedCrossRef
22.
Zurück zum Zitat Vakkila J, et al. A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatr Dev Pathol. 2005;8:43–51.PubMedCrossRef Vakkila J, et al. A basis for distinguishing cultured dendritic cells and macrophages in cytospins and fixed sections. Pediatr Dev Pathol. 2005;8:43–51.PubMedCrossRef
23.
Zurück zum Zitat Ivan P, Dominique B, Nathalie F. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. Immunol. 2007;178:2763–9. Ivan P, Dominique B, Nathalie F. Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage. Immunol. 2007;178:2763–9.
24.
Zurück zum Zitat Kim R, Emi M, Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumor and their targeted strategies for provoking tumor immunity. Clin Exp Immunol. 2006;146:189–96.PubMedCrossRef Kim R, Emi M, Tanabe K. Functional roles of immature dendritic cells in impaired immunity of solid tumor and their targeted strategies for provoking tumor immunity. Clin Exp Immunol. 2006;146:189–96.PubMedCrossRef
25.
Zurück zum Zitat Hyun K, et al. Down-regulation of cellular vascular endothelial growth factor (VEGF) levels induces differentiation of leukemic cells into leukemic-dendritic cells in patients with acute myeloid leukemia. Blood ASH (Annual Meeting Abstracts). 2005;106: 2226. Hyun K, et al. Down-regulation of cellular vascular endothelial growth factor (VEGF) levels induces differentiation of leukemic cells into leukemic-dendritic cells in patients with acute myeloid leukemia. Blood ASH (Annual Meeting Abstracts). 2005;106: 2226.
26.
Zurück zum Zitat Boorjian SA, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14:4800–8.PubMedCrossRef Boorjian SA, et al. T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res. 2008;14:4800–8.PubMedCrossRef
27.
Zurück zum Zitat Sergey V, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112:1822–31.CrossRef Sergey V, et al. Adenosine receptors in regulation of dendritic cell differentiation and function. Blood. 2008;112:1822–31.CrossRef
28.
Zurück zum Zitat Konishi J, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor—infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.PubMedCrossRef Konishi J, et al. B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor—infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 2004;10:5094–100.PubMedCrossRef
Metadaten
Titel
High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation
verfasst von
Chuan-Yong Mu
Jian-An Huang
Ying Chen
Cheng Chen
Xue-Guang Zhang
Publikationsdatum
01.09.2011
Verlag
Springer US
Erschienen in
Medical Oncology / Ausgabe 3/2011
Print ISSN: 1357-0560
Elektronische ISSN: 1559-131X
DOI
https://doi.org/10.1007/s12032-010-9515-2

Weitere Artikel der Ausgabe 3/2011

Medical Oncology 3/2011 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.